Description
Anti-Folate receptor 1 Antibody, ADCC Enchanced (BioBet-CB-016LX) is a glycosylation-modified anti-Folate receptor 1 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Folate receptor 1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Folate Receptor 1
Background
The protein encoded by this gene is a member of the folate receptor family. Members of this gene family bind folic acid and its reduced derivatives, and transport 5-methyltetrahydrofolate into cells. This gene product is a secreted protein that either anchors to membranes via a glycosyl-phosphatidylinositol linkage or exists in a soluble form. Mutations in this gene have been associated with neurodegeneration due to cerebral folate transport deficiency. Due to the presence of two promoters, multiple transcription start sites, and alternative splicing, multiple transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Oct 2009]
Alternative Names
Farletuzumab;896723-44-7;MORAb-003;LK26;MORAb-003;FOLR1;folate receptor 1 (adult);FOLR;folate receptor alpha;FR-alpha;KB cells FBP;folate binding protein;folate receptor; adult;adult folate-binding protein;ovarian tumor-associated antigen MOv18;FBP;
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-CB-016LX
Description
ADCC-Enhanced Anti-Human Folate receptor 1 (Mirvetuximab) Antibody is derived from clone Mirvetuximab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the Folate receptor 1, and it is intended for the research of Ovarian cancer, primary peritoneal cancer.
Antibody Indication
Ovarian cancer, primary peritoneal cancer
